
    
      68 patients with advanced and metastatic NSCLC have been randomized with the arm designation
      and planned intervention as follows: Arm 1: Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) Arm
      2: Docetaxel (75 mg/m2) + plinabulin (20 mg/m^2) Arm 3: Docetaxel (75 mg/m2) + plinabulin (10
      mg/m^2) Arm 4: Docetaxel (75 mg/m2) + plinabulin (5 mg/m^2)
    
  